4th Quarter - Report

HELIX, INC. for HELIX, INC.

Firm
Client
Income
—
Expenses
$75,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures Oversight of Lab Developed Tests, express legislative authority

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES New —

Contacted: Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

Continuing Resolutions and FY24 Budget Viral Surveillance funding, COVID Supplemental allocations, general HHS funding, including ASPR, AMD programs

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: Health & Human Services, Dept of (HHS); White House Office; SENATE; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.